Zealand Pharma A/S Plans $75 Million IPO for August 9th (ZEAL)
In the last year, Zealand Pharma A/S generated $48.5 million in revenue and had a net loss of $32.6 million.
Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.
Zealand Pharma A/S provided the following description of their company for its IPO: “(Note: A Public offering: “Currently, our shares are traded on Nasdaq Copenhagen A/S, or Nasdaq Copenhagen, under the symbol “ZEAL” since 2010.“) We are a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Our portfolio includes two approved products for the treatment of type 2 diabetes: (i) lixisenatide, which has been approved by the U.S. Food and Drug Administration, or FDA, and is marketed in the United States under the brand name Adlyxin and which has been approved by the European Medicines Agency, or EMA, and by other regulatory authorities outside the United States where it is marketed under the brand name Lyxumia, and (ii) a combination of lixisenatide with Lantus, the brand name of insulin glargine developed by Sanofi S.A., or Sanofi, which has been approved by the FDA and is marketed in the United States under the brand name Soliqua100/33, and has been approved by the EMA and launched in the Netherlands under the brand name Suliqua. Suliqua is expected to be launched in certain other European countries beginning in the second half of 2017. Both Adlyxin / Lyxumia and Soliquia 100/33 / Suliquia are marketed by Sanofi pursuant to a license agreement granting Sanofi commercialization rights of these products. See “—Material Contracts—Sanofi License Agreement for Lixisenatide.” “.
Zealand Pharma A/S was founded in 1997 and has 118 employees. The company is located at Smedeland 36, 2600 Glostrup, Denmark and can be reached via phone at +45 88 77 36 00 or on the web at http://www.zealandpharma.com.
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.